Increased Plasma IL-17F Levels in Rheumatoid Arthritis Patients Are Responsive to Methotrexate, Anti-TNF, and T Cell Costimulatory Modulation

Inflammation

Volumn 38, Issue 1, 2015, Pages 180-186

  Jain, Manish ^a   Attur, Mukundan ^a   Furer, Vika ^a   Todd, John ^b   Ramirez, Renita ^b   Lock, Michael ^c   Lu, Quynh A ^b   Abramson, Steven B ^a   Greenberg, Jeffrey D ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b SINGULEX INC   (United States)

^c Statistical Consultant   (United States)

Author keywords

biological markers; biologics; interleukin 17; rheumatoid arthritis

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ALPHA; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; IL17F PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DAS28; DISEASE DURATION; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; DRUG EFFECTS; METABOLISM; MIDDLE AGED; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERLEUKIN-17; MALE; METHOTREXATE; MIDDLE AGED; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925537949     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-0020-1     Document Type: Article

References (19)

1. Miossec, P., T. Korn, and V.K. Kuchroo. 2009. Interleukin-17 and type 17 helper T cells. The New England Journal of Medicine 361: 888–98.
2. Pappu, R., V. Ramirez-Carrozzi, and A. Sambandam. 2011. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology 134: 8–16.
3. Gaffen, S.L. 2009. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Current Rheumatology Reports 11: 365–70.
4. Hot, A., S. Zrioual, M.L. Toh, et al. 2011. IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. Annals of the Rheumatic Diseases 70: 341–8.
5. Zrioual, S., R. Ecochard, A. Tournadre, et al. 2009. Genome-wide comparison between IL-17A- and IL-17 F-induced effects in human rheumatoid arthritis synoviocytes. Journal of Immunology 182: 3112–20.
6. Metawi, S.A., D. Abbas, M.M. Kamal, et al. 2011. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clinical Rheumatology 30: 1201–7.
7. Chen, D.Y., Y.M. Chen, H.H. Chen, et al. 2011. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Research & Therapy 13: R126.
8. Yue, C., X. You, L. Zhao, et al. 2010. The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatology International 30: 1553–7.
9. Zhang, L., J.M. Li, X.G. Liu, et al. 2011. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. Journal of Clinical Immunology 31: 606–14.
10. Todd, J., B. Freese, A. Lu, et al. 2007. Ultrasensitive flow-based immunoassays using single-molecule counting. Clinical Chemistry 53: 1990–5.
11. Wang, T.J., K.C. Wollert, M.G. Larson, et al. 2012. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 126: 1596–604.
12. Tarawneh, R., J.M. Lee, J.H. Ladenson, et al. 2012. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 78: 709–19.
13. St Ledger, K., S.J. Agee, M.T. Kasaian, et al. 2009. Analytical validation of a highly sensitive microparticle-based immunoassay for the quantitation of IL-13 in human serum using the Erenna immunoassay system. Journal of Immunological Methods 350: 161–70.
14. van Gestel, A.M., M.L. Prevoo, M.A. van’t Hof, et al. 1996. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis and Rheumatism 39: 34–40.
15. Buch, M.H., and P. Emery. 2011. New therapies in the management of rheumatoid arthritis. Current Opinion in Rheumatology 23: 245–51.
16. Attur, M.G., R.N. Patel, S.B. Abramson, et al. 1997. Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis and Rheumatism 40: 1050–3.
17. LeGrand, A., B. Fermor, C. Fink, et al. 2001. Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis and Rheumatism 44: 2078–83.
18. Cua, D.J., and C.M. Tato. 2010. Innate IL-17-producing cells: the sentinels of the immune system. Nature Reviews. Immunology 10: 479–89.
19. Suurmond, J., A.L. Dorjee, M.R. Boon, et al. 2011. Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Research & Therapy 13: R150.